Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences (Nasdaq: SGHT) will present at two investor conferences in New York in November and December 2025. Management will present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 AM PT / 11:20 AM ET and at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 5:30 AM PT / 8:30 AM ET. Interested parties can access a live and archived webcast of each fireside chat via the company’s Investors website at https://investors.sightsciences.com/.
Sight Sciences (Nasdaq: SGHT) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025.
Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access a live and archived webcast on the company website at www.sightsciences.com under the Investors & News & Events section. The webcast replay will be available for at least 90 days after the event.
Sight Sciences (Nasdaq: SGHT) announced that two Medicare Administrative Contractors, Novitas Solutions and First Coast Service Options, established jurisdiction-wide pricing for CPT 0563T (TearCare procedure) effective for dates of service on or after January 1, 2025.
The two MACs cover an estimated 10.4 million covered lives, representing approximately 30% of Medicare fee-for-service enrollees in their jurisdictions. Claims will be payable based on individual medical necessity determinations and local fee schedules will be published on the MACs' websites.
The company also launched a Sight Access Portal to assist providers with benefit verifications and reimbursement, and said it will provide updated 2025 revenue and adjusted operating expenses guidance during its Q3 2025 earnings call.
Sight Sciences (NASDAQ:SGHT) announced the publication of a comprehensive meta-analysis in the European Journal of Ophthalmology demonstrating the long-term effectiveness of its OMNI® Surgical System for glaucoma treatment. The study, analyzing 29 publications covering 2,379 eyes, showed that 89% of patients achieved treatment success with IOP reduction ≥20% from baseline after 6-24 months.
Key findings revealed that 66-68% of patients remained medication-free after treatment, with significant IOP reductions maintained at 24 months. The system demonstrated cost-effectiveness compared to iStent inject®, with higher quality-adjusted life years (QALYs) of 8.95 over a lifetime horizon versus 8.93 for iStent inject.
Sight Sciences (NASDAQ:SGHT) announced that UnitedHealthcare (UHC) will include its OMNI® Surgical System in its expanded coverage policy for glaucoma surgical treatments, effective October 1, 2025. The coverage applies to UHC's commercial and individual exchange benefit plans, reaching approximately 30 million of UHC's over 50 million total covered lives.
The policy covers procedures including goniotomy, trabeculotomy, canaloplasty, and combined procedures for adults with mild to moderate open-angle glaucoma. The FDA-cleared OMNI Surgical System is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open angle glaucoma, and can be performed before, during, or after cataract surgery.
Sight Sciences (NASDAQ:SGHT) announced that its TearCare System has been included in the prestigious TFOS DEWS III report published in the American Journal of Ophthalmology. This recognition represents significant validation for TearCare's clinical efficacy in treating dry eye disease (DED) and meibomian gland disease (MGD).
The report highlights multiple clinical studies supporting TearCare's effectiveness, including the SAHARA trial, which demonstrated clinical superiority over Restasis in improving Tear Breakup Time and gland function, and the OLYMPIA trial, which showed significant improvement in DED symptoms, particularly in severe cases compared to LipiFlow.
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, announced its participation in the Morgan Stanley Global Healthcare Conference in New York. The company's management will deliver a presentation on Wednesday, September 10, 2025, at 10:50 am PT / 1:50 pm ET.
Investors and interested parties can access both the live and archived versions of the fireside chat through the "Investors" section on the company's website at investors.sightsciences.com.
Sight Sciences (NASDAQ: SGHT) reported Q2 2025 financial results, with total revenue of $19.6 million, declining 8% year-over-year. The company's Surgical Glaucoma segment revenue decreased 5% to $19.2 million, primarily due to Medicare coverage restrictions on multiple MIGS procedures.
Despite challenges, the company achieved positive developments including an all-time high of 1,174 Surgical Glaucoma ordering accounts, up 4% year-over-year. Operating expenses decreased 9% to $28.3 million. The company reported a net loss of $11.9 million, or $0.23 per share.
Sight Sciences raised its full-year 2025 revenue guidance to $72.0-$76.0 million while maintaining adjusted operating expenses guidance of $101.0-$105.0 million. The company ended Q2 with $101.5 million in cash and cash equivalents.
Sight Sciences (NASDAQ: SGHT) has announced positive results from a cost-utility analysis comparing its TearCare® System to cyclosporine 0.05% (CsA) for treating meibomian gland disease-associated dry eye disease. The study, published in Expert Review of Pharmacoeconomics and Outcomes Research, demonstrated significant advantages for TearCare.
The analysis revealed that TearCare delivered annual cost savings of $903 per patient ($4,916 vs. $5,819 for CsA) and achieved higher quality-adjusted life years (0.76 QALYs vs. 0.74 QALYs). The study, conducted over a one-year horizon from a US healthcare payer perspective, showed TearCare's superior cost-effectiveness even when adjusting various assumptions in scenario analyses.
Dr. Nathan Lighthizer, lead investigator and Professor at NSU Oklahoma College of Optometry, emphasized these findings align with clinical observations, highlighting TearCare as an economically sustainable treatment option.
Sight Sciences (Nasdaq: SGHT) announced the publication of 24-month results from Stage 3 of the SAHARA randomized controlled trial for its TearCare® System in treating dry eye disease. The study demonstrated significant durability, with 66% of participants requiring no additional treatment beyond the initial two treatments at baseline and Month 5.
The trial showed statistically significant improvements in all measured parameters including tear breakup time, meibomian gland secretion, and patient symptom scores. Key metrics remained improved through the 24-month period, with tear breakup time improving from 4.41 seconds at baseline to 6.29-7.13 seconds, and meibomian gland secretion scores increasing from 7.26 to 18.95.